{"id":78892,"date":"2023-09-27T14:39:47","date_gmt":"2023-09-27T09:09:47","guid":{"rendered":"http:\/\/finservwealth.com\/valiant-laboratories-ipo-sees-23-subscription-on-first-day-of-bidding\/"},"modified":"2023-09-27T14:39:47","modified_gmt":"2023-09-27T09:09:47","slug":"valiant-laboratories-ipo-sees-23-subscription-on-first-day-of-bidding","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/valiant-laboratories-ipo-sees-23-subscription-on-first-day-of-bidding\/","title":{"rendered":"Valiant Laboratories IPO sees 23% subscription on first day of bidding"},"content":{"rendered":"<p> Valiant Laboratories IPO |that focuses on manufacturing Paracetamol intends to raise Rs 152.46 crore via public issue at the upper price band, which comprises only a fresh issue component.<\/p><div id=\"finse-1190514599\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/valiant-laboratories-ipo-sees-23-subscriptionfirst-daybidding_17252511.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Valiant Laboratories IPO |that focuses on manufacturing Paracetamol intends to raise Rs 152.46 crore via public issue at the upper price band, which comprises only a fresh issue component. Valiant Laboratories IPO |that focuses on manufacturing Paracetamol intends to raise Rs 152.46 crore via public issue at the upper price band, which comprises only a fresh issue component.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/valiant-laboratories-ipo-sees-23-subscriptionfirst-daybidding_17252511.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Valiant Laboratories IPO |that focuses on manufacturing Paracetamol intends to raise Rs 152.46 crore via public issue at the upper price band, which comprises only a fresh issue component.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/valiant-laboratories-ipo-sees-23-subscriptionfirst-daybidding_17252511.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Valiant Laboratories IPO |that focuses on manufacturing Paracetamol intends to raise Rs 152.46 crore via public issue at the upper price band, which comprises only a fresh issue component. Valiant Laboratories IPO |that focuses on manufacturing Paracetamol intends to raise Rs 152.46 crore via public issue at the upper price band, which comprises only a fresh issue component.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/valiant-laboratories-ipo-sees-23-subscriptionfirst-daybidding_17252511.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Valiant Laboratories IPO |that focuses on manufacturing Paracetamol intends to raise Rs 152.46 crore via public issue at the upper price band, which comprises only a fresh issue component.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-78892","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2017\/200x200\/p\/pharma_drug_medicine_new_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/78892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=78892"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/78892\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=78892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=78892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=78892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}